A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2018
At a glance
- Drugs AZD-8186 (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 23 Mar 2018 Planned End Date changed from 1 Sep 2020 to 1 Apr 2021.
- 23 Mar 2018 Planned primary completion date changed from 1 Sep 2020 to 1 Apr 2021.